Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3362841 | 1.00 | RORC (0.39) | RORCSMN1; SMN2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3363442 | 0.80 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3363433 | 0.80 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7741971 | 0.80 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL7737731 | 0.78 | BAZ2B (0.43) | RORCSLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL3362538 | 0.78 | BAZ2B (0.43) | RORCSLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL3362323 | 0.76 | SLC6A2 (0.50) | SLC6A4SLC6A2SLC6A3MAPTMEN1 | |
| SCHEMBL20341083 | 0.75 | SLC6A2 (0.44) | SMN1; SMN2SLC6A4SLC6A2SLC6A3MAPT | |
| SCHEMBL331963 | 0.75 | SLC6A2 (0.44) | SMN1; SMN2SLC6A4SLC6A2SLC6A3MAPT | |
| SCHEMBL29757853 | 0.75 | SLC6A2 (0.44) | SMN1; SMN2SLC6A4SLC6A2SLC6A3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | RORC 4382/4885SMN1; SMN2 862/4885SLC6A4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.